close contact with the blood, with a suspected, Ebola virus infection by (IgM secretions, organs, or other probable or confirmed positive result on patient's first bodily fluids of infected Ebola case or a dead or specimen). people. High risk exists for sick animal (bats, " people when providing direct rodents, or primates) or patient care or handling dead residence in—or travel bodies (funerals). to—an endemic area Transmission via infected within 21 days of illness semen can occur up to seven onset or laboratory weeks after clinical recovery. exposure or exposure to Vaccines have been semen from a confirmed development and tried acute or convalescent following the largest case of EVD within the outbreak of Ebola in West 10 weeks of that person's Africa in 2014-2015. onset of symptoms). Generally, EVD is a severe febrile illness characterized by sudden onset of fever, and non-specific symptoms in the first 2 to 3 days e.g. severe headache, myalgia, intense weakness, sore throat, sometimes conjunctival injection, followed by 2 to 4 days period of deterioration with severe sore throat, chest, abdominal pain, maculopapular rash on trunk and shoulders, diarrhea, vomiting, impaired kidney and liver function and sometimes bleeding (petechiae, ecchymosis, from venepuncture sites, visceral hemorrhagic effusions), thrombocytopenia, leukopenia, elevated AST, ALT, abortion, hiccups, somnolence, delirium, shock, coma for fatal cases during
close contact with the blood, secretions, organs, or other bodily fluids of infected people. High risk exists for people when providing direct patient care or handling dead bodies (funerals). Transmission via infected semen can occur up to seven weeks after clinical recovery. Vaccines have been development and tried following the largest outbreak of Ebola in West Africa in 2014-2015. Generally, EVD is a severe febrile illness characterized by sudden onset of fever, and non-specific symptoms in the first 2 to 3 days e.g. severe headache, myalgia, intense weakness, sore throat, sometimes conjunctival injection, followed by 2 to 4 days period of deterioration with severe sore throat, chest, abdominal pain, maculopapular rash on trunk and shoulders, diarrhea, vomiting, impaired kidney and liver function and sometimes bleeding (petechiae, ecchymosis, from venepuncture sites, visceral hemorrhagic effusions), thrombocytopenia, leukopenia, elevated AST, ALT, abortion, hiccups, somnolence, delirium, shock, coma for fatal cases during with a suspected, probable or confirmed Ebola case or a dead or sick animal (bats, rodents, or primates) or residence in—or travel to—an endemic area within 21 days of illness onset or laboratory exposure or exposure to semen from a confirmed acute or convalescent case of EVD within the 10 weeks of that person's onset of symptoms). Ebola virus infection by (IgM positive result on patient's first specimen). "
Appendix_C_NMC_case_definitions.docx